Please login to the form below

Not currently logged in
Email:
Password:

risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

One of those new hopefuls - Rova-T for lung cancer - failed in trials but upadacitinib and anti-IL-23 antibody risankizumab (ABBV-066) remain on track after the latter reported positive

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics